Viking funds hold 6.1% of BridgeBio Pharma (NASDAQ: BBIO)

Rhea-AI Filing Summary

Viking Global Investors and related entities report beneficial ownership of 11,842,434 shares of BridgeBio Pharma, Inc. common stock, representing 6.1% of the class. This percentage is based on 193,862,871 shares outstanding as of February 12, 2026. The filing is Amendment No. 11 to a Schedule 13D and is primarily being made to remove former advisory director David C. Ott as a reporting person after his March 31, 2026 retirement, after which he is no longer a beneficial owner of the reported shares. The amendment restates the current group of reporting persons, describes their control structure, and notes that, other than transactions listed in Exhibit 99.13, no additional trades have occurred since the prior amendment.

Key Figures

Beneficial ownership: 11,842,434 shares Ownership percentage: 6.1% Shares outstanding baseline: 193,862,871 shares +2 more

5 metrics

Beneficial ownership 11,842,434 shares BridgeBio common stock reported by Viking group

Ownership percentage 6.1% Percent of BridgeBio common stock class

Shares outstanding baseline 193,862,871 shares BridgeBio common stock outstanding as of February 12, 2026

Amendment number Amendment No. 11 Amendment to Viking’s Schedule 13D on BridgeBio

Event date March 31, 2026 Date of event requiring the filing (Ott retirement)

Key Terms

beneficial ownership, Schedule 13D, joint filing agreement, voting power, +2 more

6 terms

beneficial ownership financial

"may be deemed to have beneficial ownership over any shares of Common Stock"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Schedule 13D regulatory

"this Amendment No. 11 to the ("Amendment No. 11") amends certain items of the"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

joint filing agreement regulatory

"The Reporting Persons have entered into a joint filing agreement, dated as of the date hereof"

voting power financial

"Shared Voting Power 11,842,434.00"

Voting power is the ability shareholders have to influence a company's major decisions—like electing the board, approving mergers, or changing corporate rules—based on the voting rights attached to the shares they hold. For investors it matters because greater voting power is like holding more keys to a building: it gives you a stronger say over management choices and the company’s strategy, which can affect future value and risk.

dispositive power financial

"Shared Dispositive Power 11,842,434.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

exempted limited partnership financial

"Opportunities Fund is a Cayman Islands exempted limited partnership"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 11)

BridgeBio Pharma, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

10806X102

(CUSIP Number)

Matthew Bloom
General Counsel, 600 Washington Boulevard, Floor 11
Stamford, CT, 06901
(212) 672-7059

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

03/31/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 10806X102

1

Name of reporting person

VIKING GLOBAL INVESTORS LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 11,842,434.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 11,842,434.00

11

Aggregate amount beneficially owned by each reporting person

11,842,434.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

All share percentage calculations in this Amendment No. 11 to the Schedule 13D are based on 193,862,871 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of February 12, 2026, as reported in the Issuer's annual report on Form 10-K filed with the Securities and Exchange Commission (the "Commission") on February 24, 2026.

SCHEDULE 13D

CUSIP Number(s): 10806X102

1

Name of reporting person

Viking Global Opportunities Parent GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 11,842,434.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 11,842,434.00

11

Aggregate amount beneficially owned by each reporting person

11,842,434.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 10806X102

1

Name of reporting person

Viking Global Opportunities GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 11,842,434.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 11,842,434.00

11

Aggregate amount beneficially owned by each reporting person

11,842,434.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 10806X102

1

Name of reporting person

Viking Global Opportunities Portfolio GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 11,842,434.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 11,842,434.00

11

Aggregate amount beneficially owned by each reporting person

11,842,434.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 10806X102

1

Name of reporting person

Viking Global Opportunities Illiquid Investments Sub-Master LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 11,842,434.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 11,842,434.00

11

Aggregate amount beneficially owned by each reporting person

11,842,434.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 10806X102

1

Name of reporting person

HALVORSEN OLE ANDREAS

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NORWAY

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 11,842,434.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 11,842,434.00

11

Aggregate amount beneficially owned by each reporting person

11,842,434.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 10806X102

1

Name of reporting person

Shabet Rose Sharon

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 11,842,434.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 11,842,434.00

11

Aggregate amount beneficially owned by each reporting person

11,842,434.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: BridgeBio Pharma, Inc.
(c)	Address of Issuer's Principal Executive Offices: 3160 Porter Drive, Suite 250, Palo Alto, CALIFORNIA , 94304.
Item 1 Comment: Pursuant to Rule 13d-2 under the Securities Exchange Act of 1934, as amended, this Amendment No. 11 to the Schedule 13D ("Amendment No. 11") amends certain items of the Schedule 13D filed with the Commission on July 8, 2019, as amended and supplemented by Amendment No. 1 filed with the Commission on July 19, 2023, Amendment No. 2 filed with the Commission on November 22, 2023, Amendment No. 3 filed with the Commission on August 20, 2024, Amendment No. 4 filed with the Commission on November 6, 2024, Amendment No. 5 filed with the Commission on January 31, 2025, Amendment No. 6 filed with the Commission on March 12, 2025, Amendment No. 7 filed with the Commission on July 1, 2025, Amendment No. 8 filed with the Commission on August 14, 2025, Amendment No. 9 filed with the Commission on November 14, 2025 and Amendment No. 10 filed with the Commission on February 17, 2026 (collectively, the "Schedule 13D") relating to the Common Stock, par value $0.001 per share (the "Common Stock") of BridgeBio Pharma, Inc., a Delaware corporation (the "Issuer"). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D. This Amendment No. 11 is being filed to remove Mr. David C. Ott ("Mr. Ott") as a Reporting Person from the Schedule 13D. Effective March 31, 2026, Mr. Ott retired from his roles as Advisory Director of Viking Global Investors LP ("VGI") and Executive Committee Member of each of Viking Global Partners LLC (the general partner of VGI) and Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), and accordingly is no longer a beneficial owner of any of the shares of Common Stock reported herein.
Item 2.	Identity and Background
(a)	(a) Item 2 of the Schedule 13D is hereby amended and restated in its entirety as follows: This Schedule 13D is being filed jointly on behalf of Viking Global Investors LP ("VGI"), Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), Viking Global Opportunities GP LLC ("Opportunities GP"), Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"), Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund"), O. Andreas Halvorsen and Rose S. Shabet (each, a "Reporting Person", and, collectively, the "Reporting Persons"). The Reporting Persons have entered into a joint filing agreement, dated as of the date hereof, a copy of which is filed herewith as Exhibit 99.12.
(b)	The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.
(c)	The principal business of VGI is to provide managerial services to related entities engaged in making or recommending investments in securities of public and private companies. The principal business of each of Opportunities Parent, Opportunities GP and Opportunities Portfolio GP is to serve as the general partner or sole member of related entities engaged in making or recommending investments in securities of public and private companies. The principal business of Opportunities Fund is to engage in making investments in securities of public and private companies. The present principal occupation of O. Andreas Halvorsen is Chief Executive Officer of VGI. The present principal occupation of Rose S. Shabet is Chief Operating Officer of VGI.
(d)	During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, none of the Reporting Persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	VGI is a Delaware limited partnership; Opportunities Parent, Opportunities GP and Opportunities Portfolio GP are Delaware limited liability companies; Opportunities Fund is a Cayman Islands exempted limited partnership; O. Andreas Halvorsen is a citizen of Norway; and Rose S. Shabet is a citizen of the United States.
Item 4.	Purpose of Transaction
	Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The response to Item 5(c) of this Amendment No. 11 is incorporated by reference herein.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: The information contained on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 are hereby incorporated herein by reference. The percentage of outstanding shares of Common Stock that may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated for each Reporting Person based on 193,862,871 shares of Common Stock outstanding as of February 12, 2026, as reported in the Issuer's annual report on Form 10-K filed with the Commission on February 24, 2026. Opportunities Fund has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to Opportunities Fund. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through Opportunities Fund. VGI provides managerial services to Opportunities Fund. VGI has the power to direct the voting and disposition of the shares of Common Stock directly held by Opportunities Fund. Accordingly, VGI may be deemed to have beneficial ownership over any shares of Common Stock directly owned by Opportunities Fund. Opportunities Portfolio GP serves as the general partner of Opportunities Fund and has the power to direct the voting and disposition of the shares of Common Stock directly held by Opportunities Fund. Accordingly, Opportunities Portfolio GP may be deemed to have beneficial ownership over any shares of Common Stock directly owned by Opportunities Fund. Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the power to direct the voting and disposition of the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by Opportunities Fund. Accordingly, Opportunities GP may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by Opportunities Portfolio GP, consisting of any shares of Common Stock directly owned by Opportunities Fund. Opportunities Parent serves as the sole member of Opportunities GP, which has the power to direct the voting and disposition of the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by Opportunities Fund. Accordingly, Opportunities Parent may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by Opportunities GP, consisting of any shares of Common Stock directly owned by Opportunities Fund. Mr. Halvorsen and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (the general partner of VGI) and Opportunities Parent, have shared authority to direct the voting and disposition of the shares of Common Stock beneficially owned by VGI and Opportunities Parent. Accordingly, each of Mr. Halvorsen and Ms. Shabet may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by VGI and Opportunities Parent. Except as disclosed in this Amendment No. 11, none of the Reporting Persons beneficially owns any shares of Common Stock or has the right to acquire any shares of Common Stock. Except as disclosed in this Amendment No. 11, none of the Reporting Persons presently has the power to vote or to direct the voting or to dispose or direct the disposition of any shares of Common Stock that such Reporting Person may be deemed to beneficially own.
(b)	Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows: The information contained on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 are hereby incorporated herein by reference.
(c)	Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: Except for the transactions listed in Exhibit 99.13 of this Amendment No. 11, the Reporting Persons have not effected any transactions in the Common Stock since the filing of Amendment No. 10 on February 17, 2026.
Item 7.	Material to be Filed as Exhibits.
	Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit 99.12 - Joint Filing Agreement, dated as of April 2, 2026, among the Reporting Persons Exhibit 99.13 - Schedule of Transactions

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

VIKING GLOBAL INVESTORS LP

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)
Date:	04/02/2026

Viking Global Opportunities Parent GP LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)
Date:	04/02/2026

Viking Global Opportunities GP LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)
Date:	04/02/2026

Viking Global Opportunities Portfolio GP LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)
Date:	04/02/2026

Viking Global Opportunities Illiquid Investments Sub-Master LP

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)
Date:	04/02/2026

HALVORSEN OLE ANDREAS

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of HALVORSEN OLE ANDREAS (1)
Date:	04/02/2026

Shabet Rose Sharon

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Shabet Rose Sharon (2)
Date:	04/02/2026

Comments accompanying signature:

(1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).

FAQ

What ownership stake does Viking report in BridgeBio Pharma (BBIO)?

Viking and its related entities report beneficial ownership of 11,842,434 BridgeBio Pharma common shares, equal to 6.1% of the outstanding stock. This percentage is calculated using 193,862,871 shares outstanding as of February 12, 2026, from BridgeBio’s Form 10-K.

Why did Viking file Amendment No. 11 to its Schedule 13D for BBIO?

Amendment No. 11 updates Viking’s Schedule 13D mainly to remove David C. Ott as a reporting person. He retired effective March 31, 2026, from roles at Viking affiliates and is no longer a beneficial owner of the BridgeBio common shares reported.

Who are the current reporting persons on Viking’s BridgeBio Pharma 13D/A?

Current reporting persons are Viking Global Investors LP, several Viking Global Opportunities entities, Viking Global Opportunities Illiquid Investments Sub-Master LP, and individuals O. Andreas Halvorsen and Rose S. Shabet. They have entered into a joint filing agreement dated April 2, 2026.

How is voting and dispositive power over BridgeBio (BBIO) shares structured for Viking?

The 11,842,434 BridgeBio shares are directly owned by Opportunities Fund, with voting and dispositive power shared through its general partner and related Viking entities. VGI and various Opportunities GPs may be deemed to share beneficial ownership through their control relationships.

Did Viking report recent trading activity in BridgeBio Pharma stock?

The amendment states that, except for transactions listed in Exhibit 99.13, the reporting persons have not effected any BridgeBio common stock trades since Amendment No. 10, which was filed on February 17, 2026. Details of those trades are contained in the exhibit schedule.

What type of filing is this BridgeBio Pharma (BBIO) document from Viking?

This document is a Schedule 13D/A Amendment No. 11, updating Viking’s beneficial ownership disclosure in BridgeBio Pharma’s common stock. It refines the list of reporting persons and confirms their 6.1% stake based on the company’s latest reported shares outstanding.